1. 3335 Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses. (September 2015) Authors: Andtbacka, R.H.I.; Curti, B.; Kaufman, H.L.; Daniels, G.A.; Nemunaitis, J.J.; Spitler, L.E.; Hallmeyer, S.; Lutzky, J.; Schultz, S.; Whitman, E.D.; Zhou, K.; Karpathy, R.; Weisberg, J.I.; Shafren, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3336 Phase II CALM extension study: Enhanced immune-cell infiltration within the tumour micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21. (September 2015) Authors: Andtbacka, R.H.I.; Curti, B.; Hallmeyer, S.; Feng, Z.; Paustian, C.; Bifulco, C.; Fox, B.; Grose, M.; Davies, B.; Karpathy, R.; Shafren, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S677 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗